These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 30361422)
1. Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. Ueda H; Kawakami H; Nonagase Y; Takegawa N; Okuno T; Takahama T; Takeda M; Chiba Y; Tamura T; Nakagawa K Oncologist; 2019 Feb; 24(2):163-e76. PubMed ID: 30361422 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer. Ueda S; Kawakami H; Nishina S; Sakiyama T; Nonagase Y; Okabe T; Tamura T; Nakagawa K Cancer Chemother Pharmacol; 2015 Aug; 76(2):279-85. PubMed ID: 26050210 [TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment. Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336 [TBL] [Abstract][Full Text] [Related]
4. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study. Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686 [TBL] [Abstract][Full Text] [Related]
6. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118 [TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma. Yajima S; Suzuki T; Nanami T; Oshima Y; Kikuchi Y; Funahashi K; Shimada H Ann Thorac Cardiovasc Surg; 2021 Aug; 27(4):219-224. PubMed ID: 33408308 [TBL] [Abstract][Full Text] [Related]
8. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N; Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001 [TBL] [Abstract][Full Text] [Related]
10. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study. Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249 [TBL] [Abstract][Full Text] [Related]
11. [Safety and Efficacy of Neoadjuvant Chemotherapy(UDON: 5-FU, Docetaxel, and Nedaplatin)for Esophageal Cancer]. Konishi T; Komatsu S; Takeda R; Kanazawa H; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y Gan To Kagaku Ryoho; 2023 Dec; 50(13):1381-1383. PubMed ID: 38303281 [TBL] [Abstract][Full Text] [Related]
12. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum. Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Combination Chemotherapy With Docetaxel, Nedaplatin, and 5-Fluorouracil for Advanced and Recurrent Esophageal Cancer. Sohda M; Hara K; Kuriyama K; Tateno K; Uchida S; Watanabe T; Shibasaki Y; Saito H; Nakazawa N; Sano A; Sakai M; Yokobori T; Ogawa H; Shirabe K; Saeki H Anticancer Res; 2024 Mar; 44(3):1309-1315. PubMed ID: 38423646 [TBL] [Abstract][Full Text] [Related]
14. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer. Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181 [TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281 [TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant Triplet Combination Chemotherapy(UDON Therapy)in Esophageal Cancer Patients with Impaired Renal Function-A Retrospective Study]. Kimura Y; Shiraishi O; Iwama M; Kato H; Kawakami H; Okuno T; Hiraki Y; Yasuda A; Shinkai M; Imano M; Nakagawa K; Yasuda T Gan To Kagaku Ryoho; 2019 Dec; 46(13):2173-2175. PubMed ID: 32156869 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma. Peng PJ; Lv BJ; Tang C; Liao H; Lin Z; Liu YM; Wang ZH; Wang SY; Cheng ZB Drug Des Devel Ther; 2015; 9():6401-5. PubMed ID: 26677316 [TBL] [Abstract][Full Text] [Related]
19. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097 [TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Unresectable Esophageal Cancer. Takahashi K; Osaka Y; Ota Y; Watanabe T; Iwasaki K; Tachibana S; Nagakawa Y; Katsumata K; Tsuchida A Anticancer Res; 2020 May; 40(5):2827-2832. PubMed ID: 32366430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]